Literature DB >> 7373338

A double blind study of metoclopramide in the treatment of migraine attacks.

P Tfelt-Hansen, J Olesen, A Aebelholt-Krabbe, B Melgaard, B Veilis.   

Abstract

One hundred and fifty patients with migraine attacks attending the Copenhagen acute migraine clinic were treated either with metoclopramide 10 mg i.m. metoclopramide 20 mg as suppository or placebo in a double blind trial. All patients simultaneously or 30 minutes later received paracetamol 1 g and diazepam 5 mg orally. The nausea was relieved in 71% of the patients by placebo and bed rest, but metoclopramide was significantly (p = 0.04) more effective and relieved nausea in 86% of the patients. Metoclopramide did not by itself reduce the pain, but enhanced the effect of the analgesic or sedative medication. This effect, however, just failed to be statistically significant (p = 0.06).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373338      PMCID: PMC490544          DOI: 10.1136/jnnp.43.4.369

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  The Copenhagen Acute Headache Clinic: organization, patient material and treatment results.

Authors:  J Olesen; A Aebelholt; B Veilis
Journal:  Headache       Date:  1979-05       Impact factor: 5.887

2.  Metoclopramide in the treatment of migraine.

Authors:  S G Matts
Journal:  Practitioner       Date:  1974-06

3.  Some clinical features of the acute migraine attack. An analysis of 750 patients.

Authors:  J Olesen
Journal:  Headache       Date:  1978-11       Impact factor: 5.887

4.  The effect of metoclopramide on the absorption of effervescent aspirin in migraine.

Authors:  G N Volans
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

Review 5.  Metoclopramide: a review of its pharmacological properties and clinical use.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Absorption of effervescent aspirin during migraine.

Authors:  G N Volans
Journal:  Br Med J       Date:  1974-11-02
  6 in total
  10 in total

1.  Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine.

Authors:  A M Kelly; M Ardagh; C Curry; J D'Antonio; S Zebic
Journal:  J Accid Emerg Med       Date:  1997-07

2.  New Prescriptions for Migraine in the Emergency Department: Treating a common affliction and presenting symptom.

Authors:  P L Lane
Journal:  Can Fam Physician       Date:  1992-06       Impact factor: 3.275

Review 3.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

4.  Aspirin pharmacokinetics in migraine. The effect of metoclopramide.

Authors:  L M Ross-Lee; M J Eadie; V Heazlewood; F Bochner; J H Tyrer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Inpatient management of migraine.

Authors:  Michael J Marmura; Stephanie Wrobel Goldberg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

6.  Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.

Authors:  Ian Colman; Michael D Brown; Grant D Innes; Eric Grafstein; Ted E Roberts; Brian H Rowe
Journal:  BMJ       Date:  2004-11-18

Review 7.  Update of Inpatient Treatment for Refractory Chronic Daily Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 8.  Newer formulations of the triptans: advances in migraine management.

Authors:  Jonathan Paul Gladstone; Marek Gawel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Treatment of childhood headaches.

Authors:  A Gupta; A D Rothner
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 6.030

10.  Which is more effective for the treatment of Acute Migraine Attack: Dexketoprofen, Ibuprofen or Metoclopramide?

Authors:  Sinan Karacabey; Erkman Sanri; Sercan Yalcinli; Haldun Akoglu
Journal:  Pak J Med Sci       Date:  2018 Mar-Apr       Impact factor: 1.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.